Financial Performance - The company achieved total operating revenue of RMB 114,166.94 million, a year-on-year increase of 9.94%[6] - The net profit attributable to the parent company was RMB 14,777.58 million, a decrease of 24.00% compared to the previous year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 12,538.61 million, down 28.12% year-on-year[6] - Basic earnings per share decreased by 31.52% to RMB 1.26 due to increased share capital and declining order prices[7] Assets and Equity - Total assets at the end of the reporting period were RMB 321,954.08 million, reflecting a growth of 16.00% from the beginning of the period[6] - Equity attributable to the parent company increased by 47.83% to RMB 239,192.77 million[6] Return on Equity - The company’s weighted average return on equity decreased by 5.09 percentage points to 7.76%[3] Market Conditions - The company faced negative impacts on operating profit due to intensified competition and declining gross margins in the pharmaceutical industry[6] Capital Increase - The company increased its share capital by 33.33% through a public offering of ordinary shares (A shares) in 2024[7] Audit Status - The financial data disclosed is preliminary and subject to final audit in the 2024 annual report[8]
益诺思(688710) - 2024 Q4 - 年度业绩